The New York State Department of Financial Services has charged the drug manufacturer Mallinckrodt with fraudulent insurance acts and intentional misrepresentation of facts, arguing that the company contributed to the opioid crisis in the United States by downplaying the risks and overstating the benefits of long-term opioid use.

U.K.-based Mallinckrodt is the first company charged in a broader DFS investigation into the opioid crisis, according to the agency.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]